The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1098-1103

  Steward, W P ^a   Middleton, M ^b   Benghiat, A ^a   Loadman, P M ^c   Hayward, C ^d   Waller, S ^d   Ford, S ^e   Halbert, G ^e   Patterson, L H ^c   Talbot, D ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bioreductive; Pharmacodynamics; Pharmacokinetics; Phase I study

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INFECTION; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIA; TUMOR BIOPSY; TUMOR VOLUME; URINE;

EID: 34447312859     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm120     Document Type: Article

References (19)

1. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
2. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
3. Siewert JR, Stein HJ, Sendler A et al. Oesophageal cancer: Clinical management. In Kelsen DA (ed): Principles and Practice of Gastrointestinal Oncology. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 261-289.
4. Brown JM. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 157-162.
5. Rockwell S, Moulder JE. Hypoxic fractions of solid tumours: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1884; 10: 695-712.
6. Raleigh SM, Wangoho E, Burke MD et al. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 1998; 42: 763-767.
7. Patterson LH, McKeown SR, Robinson T et al. Antitumour prodrug development rising cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 1999; 14: 473-486.
8. McKeown SR, Hejmadi MV, McIntyre IA et al. AQ4N - an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in-vivo. Br J Cancer 1995; 72: 26-81.
9. McKeown SR, Friery OP, McIntyre IA et al. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 1996; 74: S39-S42.
10. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Metastasis Rev 1993; 12: 119-134.
11. Wilson WR, Denny WA, Pullen SM et al. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitra N-oxide and AQ4N. Br J Cancer 1996; 74: S43-S47.
12. Hejamadi MV, McKeown SR, Friery OP et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypotoxic tumour cells. Br J Cancer 1996; 73: 499-505.
13. Patterson LH, McKeown SR, Ruparelia K et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000; 82: 1984-1990.
14. Swaine DJ, Loadman PM, Bibby MC et al. High-performance liquid chromatographic analysis of AQ4N-an alkylaminoanthraquinone N-oxide. J Chromatogr 2000; 742: 239-245.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Loadman PM, Swaine DJ, Bibby MC et al. A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab Dispos 2001; 29: 422-426.
17. Stratton JA, Byfield PE, Byfield JE et al. A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest 1975; 56: 88-97.
18. Reckzeh B, Merte H, Pfluger KH et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14: 1071-1076.
19. Fuks Z, Strober S, Bobrove AM et al. Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease. J Clin Invest 1976; 58: 803-814.